Estrogenic and antiestrogenic activities of 16α- and 2-hydroxy metabolites of 17β-estradiol in MCF-7 and T47D human breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 67, Issue 5-6, 1998, Pages 413-419

  Gupta, Mona ^a   McDougal, Andrew ^a   Safe, Stephen ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRADIOL; 2 HYDROXYESTRONE; CATHEPSIN D; CREATINE KINASE; ESTRADIOL; ESTRIOL; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; ESTROGEN ACTIVITY; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; MITOGENESIS; PROMOTER REGION; REPORTER GENE; TRANSACTIVATION;

BREAST NEOPLASMS; CATHEPSIN D; CELL DIVISION; CREATINE KINASE; ESTRADIOL; ESTRIOL; FEMALE; HUMANS; HYDROXYESTRONES; ISOENZYMES; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032448464     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00135-6     Document Type: Article

References (46)

1. 1. Hulka B. S., Liu E. T. and Lininger R. A., Steroid hormones and risk of breast cancer. Cancer 74 (1994) 1111-1124.
2. 2. Hulka B. S., Breast cancer: cause and prevention. Lancet 346 (1995) 883-887.
3. 3. Smith D. C., Prentice R., Thompson D. J. and Herrmann W. L., Association of exogenous estrogen and endometrial carcinoma. N. Engl. J. Med. 293 (1975) 1164-1167.
4. 4. Liehr J. G., Hormone-associated cancer: mechanistic similarities between human breast cancer and estrogen-induced kidney carcinogenesis in hamsters. Environ. Health Perspect. 105 (1997) 565-569.
5. 5. Liehr J. G., Genotoxic effects of estrogens. Mutat. Res. 238 (1990) 269-276.
6. 6. Liehr J. G., Ricci M. J., Jefcoate C. R., Hannigan E. V., Hokanson J. A. and Zhu B. T., 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc. Natl Acad. Sci. USA 92 (1995) 9220-9224.
7. 7. Liehr J. G. and Ricci M. J., 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl Acad. Sci. USA 93 (1996) 3294-3296.
8. 8. Abul-Hajj Y. J., Tabakovic K. and Tabakovic I., An estrogen-nucleic acid adduct. Electroreductive intermolecular coupling of 3,4-estrone-o-quinone and adenine. J. Am. Chem. Soc. 117 (1995) 6144-6145.
9. 9. Tabakovic K., Gleason W. B., Ojala W. H. and Abul-Hajj Y. J., Oxidative transformation of 2-hydroxyestrone. Stability and reactivity of 2,3-estrone quinone and its relationship to estrogen carcinogenicity. Chem. Res. Toxicol. 9 (1996) 860-865.
10. 10. Cavalieri E. L., Stack D. E., Devanesan P. D., Todorovic R., Dwivedy I., Higginbotham S., Johansson S. L., Patil K. D., Gross M. L., Gooden J. K., Ramanathan R., Cerny R. L. and Rogan E. G., Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl Acad. Sci. USA 94 (1997) 10937-10942.
11. 11. Bradlow H. L., Telang N. T., Sepkovic D. W. and Osborne M. P., 2-Hydroxyestrone: the "good" estrogen. J. Endocrinol. 150 (1996) S259-S263.
12. 12. Bradlow H. L., Davis D. L., Lin G., Sepkovic D. and Tiwari R. K., The ratio of 16α/2-hydroxyestrone as a biologic marker of breast cancer risk. Environ. Health Perspect. 103 (1995) 147-150.
13. 13. Schneider J., Kinne D., Fracchia A., Pierce V., Anderson K. E., Bradlow H. I. and Fishman J., Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc. Natl Acad. Sci. USA 79 (1982) 3047-3051.
14. 14. Telang N. T., Bradlow H. L. and Osborne M. P., Molecular and endocrine biomarkers in non-involved breast: relevance to cancer chemoprevention. J. Cell Biochem. 16G (Suppl.) (1992) 161-169.
15. 15. Osborne M. P., Bradlow H. L., Wong G. Y. and Telang N. T., Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J. Natl Cancer Inst. 85 (1993) 1917-1920.
16. 16. Bradlow H. L., Hersheopf R. J., Martucci C. P. and Fishman J., Estradiol 16z-hydroxylation in the mouse correlate with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc. Natl Acad. Sci. USA 82 (1985) 6295-6299.
17. 17. Adlercreutz H., Gorbach S. L., Goldin B. R., Woods M. N., Dwyer J. T. and Hämäläinen E., Estrogen metabolism and excretion in Oriental and Caucasian women. J. Natl Cancer Inst. 86 (1994) 1076-1082.
18. 18. Adlercreutz H., Fotsis T., Bannwart C., Hämäläinen E., Bloigu S. and Ollus A., Urinary estrogen profile determination in young Finnish vegetarian and omnivorous women. J. Steroid Biochem. 24 (1986) 289-296.
19. 19. Adlercreutz H., Fotsis T., Höckerstedt K., Hämäläinen E., Bannwart C., Bloigu S., Valtonen A. and Ollus A., Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. J. Steroid Biochem. 34 (1989) 527-530.
20. 1) in postmenopausal women with and without breast cancer. Environ. Health Perspect. 105S (1997) 601-605.
21. 21. Bradlow H. L., Davis D. L., Lin G., Sepkovic D. and Tiwari R., Effects of pesticides on the ratio of 16α/2-hydroxyestrone: a biologic marker of breast cancer risk. Environ. Health Perspect. 103 (1995) 147-150.
22. 22. McDougal A. and Safe S., Induction of 16α-/2-hydroxyestrone metabolite ratios in MCF-7 cells by pesticides, carcinogens and antiestrogens does not predict mammary carcinogens. Environ. Health Persp. 106 (1998) 203-206.
23. 23. Swaneck G. E. and Fishman J., Covalent binding of the endogenouse estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc. Natl Acad. Sci. USA 85 (1988) 7831-7835.
24. 24. Schneider J., Huh M. M., Bradlow H. L. and Fishman J., Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J. Biol. Chem. 259 (1984) 4840-4845.
25. 25. Schütze N., Vollmer G. and Knuppen R., Catecholestrogens are agonists of estrogen receptor dependent gene expression in MCF-7 cells. J. Steroid Biochem. Mol. Biol. 48 (1994) 453-461.
26. 26. Schütze N., Vollmer G., Tiemann I., Geiger M. and Knuppen R., Catecholestrogens are MCF-7 cell estrogen receptor agonists. J. Steroid Bioehem. Mol. Biol. 46 (1993) 781-789.
27. 27. Redecker B., Heckendorf B., Grosch H., Mersmann G. and Hasilik A., Molecular organization of the human cathepsin D gene. DNA Cell Biol. 10 (1991) 423-431.
28. 28. Hobson G. M., Molloy G. R. and Benfield P. A., Identification of cis-acting regulatory elements in the promoter region of the rat brain creatine kinase gene. Mol. Cell. Biol. 10 (1990) 6533-6543.
29. 29. May F. E. and Westley B. R., Identification and characterization of estrogen-regulated RNAs in human breast cancer cells. J. Biol. Chem. 263 (1988) 12901-12908.
30. 30. Wöffle D., Munzel P., Fischer G. and Bock K. W., Altered growth control of rat hepatocytes after treatment with 3,4,3′,4′-tetrachlorobiphenyl in vivo and in vitro. Carcinogenesis 9 (1988) 919-924.
31. 31. Manning D. L., Archibald L. H. and Ow K. T., Cloning of estrogen-responsive messenger RNAs in the T-47D human breast cancer cell line. Cancer Res. 50 (1990) 4098-4104.
32. 32. Dotzlaw H., Leygue E., Watson P. H. and Murphy L. C., Expression of estrogen receptor-β in human breast tumors. J. Clin. Endocrinol. Metab. 82 (1997) 2371-2374.
33. 33. Kalkhoven E., Kwakkenbos-Isbrucker L., De Laat S. W., Van der Saag P. T. and Van der Burg B., Synthetic progestins induce proliferation of breast tumor cell lines via the progesterone or estrogen receptor. Mol. Cell Endocrinol. 102 (1994) 45-52.
34. 34. Clarke C. L., Roman S. D., Graham J., Koga M. and Sutherland R. L., Progesterone receptor regulation by retinoic acid in the human breast cancer cell line T-47D. J. Biol. Chem. 265 (1990) 12694-12700.
35. 35. Sartorius C. A., Groshong S. D., Miller L. A., Powell R. L., Tung L., Takimoto G. S. and Horwitz K. B., New T47D breast cancer cell lines for the independent study of progesterone B-and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res. 54 (1994) 3868-3877.
36. 36. Archer T. K., Zaniewski E., Moyer M. L. and Nordeen S. K., The differential capacity of glucocorticoids and progestins to alter chromatin structure and induce gene expression in human breast cancer cells. Mol. Endocrinol. 8 (1994) 1154-1162.
37. 37. Cleutjens K. B., van Eekelen C. C., van der Korput H. A., Brinkmann A. O. and Trapman J., Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol Chem. 271 (1996) 6379-6388.
38. 38. Chalbos D., Haagensen D., Parish T. and Rochefort H., Identification and androgen regulation of two proteins released by T47D human breast cancer cells. Cancer Res. 47 (1987) 2787-2792.
39. 39. Tilley W. D., Marcelli M. and McPhaul M. J., Expression of the human androgen receptor gene utilizes a common promoter in diverse human tissues and cell lines. J. Biol. Chem. 265 (1990) 13776-13781.
40. 40. Scheller A., Scheinman R. I., Thompson E., Scarlett C. O. and Robins D. M., Contextual dependence of steroid receptor function on an androgen-responsive enhancer. Mol. Cell Endocrinol 121 (1996) 75-86.
41. 41. Hsieh M. L., Charlesworth M. C., Goodmanson M., Zhang S., Seay T., Klee G. G., Tindall D. J. and Young C. Y., Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. Cancer Res. 57 (1997) 2651-2656.
42. 42. Fitzgerald P., Teng M., Chandraratna R. A., Heyman R. A. and Allegretto E. A., Retinoic acid receptor α expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res. 57 (1997) 2642-2650.
43. 43. Kilgore M. W., Tate P. L., Rai S., Sengoku E. and Price T. M., MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response. Mol. Cell Endocrinol. 129 (1997) 229-235.
44. 44. Fernandez P., Burghardt R., Smith R., Nodland K. and Safe S., High passage T47D human breast cancer cells: altered endocrine and 2,3,7,8-tetrachlorodibenzo-p-dioxin responsiveness. Eur. J. Pharmacol 270 (1994) 53-66.
45. 45. Fernandez P. and Safe S., Growth inhibitory and antimitogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in T47D human breast cancer cells. Toxicol. Lett. 61 (1992) 185-197.
46. 46. Das R. and Vonderhaar B. K., Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res. Treat. 40 (1996) 141-149.